Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
6,695 results
  • MiR-122 Promotes the Development of Colon Cancer by Targeting ALDOA In Vitro. [Journal Article]
    Technol Cancer Res Treat 2019; 18:1533033819871300Li H, Zhang X, … Li Z
  • Non-coding RNAs, originally considered junk gene products, have taken center stage in view of their significant involvement in a spectrum of biological processes during human development, thereby offering novel therapeutic targets for improvement of treatment options. Accumulating evidence has demonstrated non-coding RNA dysfunction across various human cancers. In particular, microRNAs have emer…
  • S-glycosylation-based cysteine profiling reveals regulation of glycolysis by itaconate. [Journal Article]
    Nat Chem Biol 2019; 15(10):983-991Qin W, Qin K, … Wang C
  • Itaconate has been recently recognized as an anti-inflammatory metabolite involved in the pathogen-macrophage interface. Due to its weak electrophilicity, itaconate could modify cysteines of the protein KEAP1 and glutathione, which contribute to its anti-inflammatory effect. However, the substrates of itaconate modification in macrophages have not been systematically profiled, which largely imped…
  • Computational and Experimental Studies of Inhibitor Design for Aldolase A. [Journal Article]
    J Phys Chem B 2019; 123(28):6034-6041Qi R, Walker B, … Ren P
  • Glycolytic enzyme fructose-bisphosphate aldolase A is an emerging therapeutic target in cancer. Recently, we have solved the crystal structure of murine aldolase in complex with naphthalene-2,6-diyl bisphosphate (ND1) that served as a template of the design of bisphosphate-based inhibitors. In this work, a series of ND1 analogues containing difluoromethylene (-CF2), methylene (-CH2), or aldehyde …
New Search Next